Sulforaphane Improves Liver Metabolism and Gut Microbiota in Circadian Rhythm Disorder Mice Models Fed With High-Fat Diets.
Level 5 - mechanism / opinion, no new human data
Preclinical animal study
PubMed 39361249 · doi:10.1002/mnfr.202400535
What was done
Researchers established a shifted circadian rhythm (CR) mouse model fed a high-fat diet (HFD) and tested the effects of sulforaphane (SFN). Hepatic lipid accumulation and intestinal inflammatory damage were assessed using hematoxylin and eosin staining and Oil Red O staining. Hepatic metabolites were evaluated with targeted metabolomics, gut microbiota composition was analyzed via 16S rRNA gene sequencing, and CR protein expression was measured in the hypothalamus and liver tissues.
What was found
The abstract reports no numerical values, statistical metrics, or effect sizes. Qualitatively, SFN improved liver lipid accumulation and intestinal inflammatory damage in shifted CR mice on an HFD. SFN increased hepatic amino acid metabolite concentrations and significantly decreased bile acid metabolites. Sequencing showed SFN increased beneficial bacteria, including Lachnospiraceae, Lactobacillus, Alistipes, Akkermansia, and Eubacterium coprostanoligenes, which correlated with hepatic metabolites. SFN also significantly regulated CR protein expression in hypothalamus and liver tissues.
Why it matters
This study suggests sulforaphane may help mitigate metabolic and microbiome disruptions associated with circadian misalignment and high-fat diet intake.
Limits
The study is in a mouse model, limiting direct translation to humans. The abstract omits sample size, SFN dose, exposure duration, and all quantitative data.
Cited by
- contradicts Sulforaphane stimulates bile salt biosynthesis.